News

Boehringer Ingelheim Acquires Enleofen’s Anti-IL-11 Therapeutic Platform for Fibrotic Diseases

Boehringer Ingelheim has acquired the worldwide exclusive rights to Enleofen‘s interleukin-11 (IL-11) platform, designed for the treatment of fibrotic diseases such as pulmonary fibrosis. This newly established partnership brings together Boehringer Ingelheim’s expertise and substantial pipeline in fibrotic diseases, and Enleofen’s knowledge of IL-11 biology. Enleofen…

Top 10 Pulmonary Fibrosis Stories of 2019

Throughout 2019, Pulmonary Fibrosis News provided you daily coverage of breakthrough discoveries, promising therapies, and clinical trials related to pulmonary fibrosis (PF). As we look forward to bringing more news to patients, family members, and caregivers dealing with PF in 2020, here are the top 10 most-read articles of 2019,…